Herceptin (trastuzumab)
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Herceptin (Trastuzumab) injection was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumor cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.
Herceptin IV, either alone or in combination with targeted therapies/chemotherapies is indicated for the treatment of patients with HER2-positive early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer or cancer of the gastro-esophageal junction.
If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]
In case of any adverse events or safety queries, please contact: [email protected]
If you have a scientific query related to one of Roche's products, please contact: [email protected]
M-PK-00001707
Solutions
Pharma Products
![[Product] Herceptin](https://assets.roche.com/f/169232/409x230/44b9118240/herceptin.jpeg/m/320x180/filters:format(webp):quality(90)/)